21 completed, 12 unknown, 3 terminated, 2 recruiting. 13 Phase 3, 8 Phase 4, 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 11, Terminated 1, Unknown 1 |
| Phase 4 | 8 | Completed 4, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Unknown 2, Recruiting 1 |
| Phase 1 | 2 | Unknown 2 |
Follow Antirheumatic Agents: new trials by email Literature Review of Antirheumatic Agents trials Research Report on Antirheumatic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| L-carnitine Supplementation in Rheumatoid Arthritis Patients Carnitine, Disease-modifying anti-rheumatic drugs - Rheumatoid Arthritis (RA) | Phase 2 | Recruiting | German University in Cairo | 60 | 2024-12-31 | 2025-01-07 |
| Effectiveness of Probiotics in Patients of Mild to Moderate Rheumatoid Arthritis probiotic plus standard treatment, standard treatment - Rheumatoid Arthritis | Phase 3 | Completed | King Edward Medical University | 88 | 2023-08-24 | 2024-09-19 |
| Outcomes of Biological Therapy on Rheumatoid Arthritis Biological Drug - Rheumatoid Arthritis | Unknown | Sohag University | 200 | 2022-06-01 | 2022-03-21 | |
| Cortisol Circadian Rhythm in Patients With RA DMARDs - Rheumatoid Arthritis | Unknown | National and Kapodistrian University of Athens | 50 | 2022-02-02 | 2023-01-04 | |
| China National Registry of Neuro-Inflammatory Diseases Intravenous steroid - Multiple Sclerosis, NMO Spectrum Disorder | Recruiting | Beijing Tiantan Hospital | 10000 | 2021-12-15 | 2023-07-21 | |
| PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors DMARDs, biologic DMARDs, JAK Inhibitor - Arthritis, Rheumatoid, Arthritis, Psoriatic | Unknown | Liga Panamericana de Asociaciones de Reumatologia (PANLAR) | 3000 | 2021-03-01 | 2021-03-29 | |
| Predictive Factors for COVID-19 in Rheumatology Disease-modifying antirheumatic drugs (DMARDs) - Rheumatic Diseases, Covid19 | Unknown | Fundación Santa Fe de Bogota | 150 | 2020-10-01 | 2020-09-28 | |
| Immunosuppressant Combined With Pirfenidone in CTD-ILD Pirfenidone, DMARDs - Pirfenidone, Connective Tissue Diseases | Phase 4 | Unknown | Qilu Hospital of Shandong University | 200 | 2019-08-16 | 2023-11-18 |
| Rheumatoid Arthritis Memory B Cells and Abatacept Abatacept, DMARDs - Rheumatoid Arthritis | Phase 4 | Completed | NYU Langone Health | 25 | 2019-06-02 | 2024-07-03 |
| Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase patient treated with DMARD - Rheumatoid Arthritis | Unknown | University Hospital, Toulouse | 594226 | 2018-11-20 | 2019-06-10 | |
| A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) Peficitinib, Plaebo, Disease-modifying antirheumatic drugs (DMARDs) - Rheumatoid Arthritis (RA) | Phase 3 | Completed | Astellas Pharma China, Inc. | 385 | 2018-09-27 | 2024-10-21 |
| Optimal MTX Dose With Folic Acid Randomized Case-control Trial MTX, Folic Acid, DMARDs - Rheumatoid Arthritis | Phase 4 | Unknown | Sun Yat-sen University | 160 | 2018-08-01 | 2019-08-26 |
| Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND) disease modified antirheumatic drugs or biological agents - Rheumatoid Arthritis | Unknown | Nanfang Hospital, Southern Medical University | 200 | 2018-05-13 | 2018-05-14 | |
| Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors Antiinflammatory/DMARDs - Immune-related Adverse Event | Completed | Diakonhjemmet Hospital | 69 | 2018-03-05 | 2025-08-24 | |
| Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis hUC-MSC + DMARDs, DMARDs - Rheumatoid Arthritis | Phase 1 | Unknown | Shenzhen Hornetcorn Bio-technology Company, LTD | 40 | 2016-01-01 | 2016-05-24 |
| An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement Infliximab, NSAIDs, DMARDs - Spondylitis, Ankylosing | Terminated | Janssen Research & Development, LLC | 76 | 2015-04-10 | 2017-11-01 | |
| A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent Tocilizumab, DMARDs, Oral Corticosteroids - Rheumatoid Arthritis | Phase 3 | Completed | Hoffmann-La Roche | 162 | 2014-03-04 | 2018-12-07 |
| A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Tocilizumab, DMARDs - Rheumatoid Arthritis | Phase 3 | Completed | Hoffmann-La Roche | 227 | 2013-09-05 | 2017-07-11 |
| A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis DMARD, methotrexate, tocilizumab [RoActemra/Actemra] - Rheumatoid Arthritis | Phase 3 | Completed | Hoffmann-La Roche | 401 | 2013-09-01 | 2018-01-26 |
| A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis DMARDs - Combination With DMARDs | Phase 3 | Unknown | Mycenax Biotech Inc. | 98 | 2013-09-01 | 2018-04-17 |
Showing 20 of 39. Sign in to see all of them.
Arthritis, Rheumatoid (33) · Rheumatic Diseases (2) · Arthritis (1) · Arthritis, Psoriatic (1) · Arthritis, Reactive (1) · Autoimmune Diseases (1) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Connective Tissue Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Encephalomyelitis, Acute Disseminated (1) · Joint Diseases (1) · Lung Diseases, Interstitial (1) · Multiple Sclerosis (1)
Hoffmann-La Roche (9) · Pfizer (3) · JW Pharmaceutical (2) · Alliancells Bioscience Corporation Limited (1) · Amgen (1) · Astellas Pharma China, Inc. (1) · Barts & The London NHS Trust (1) · Beijing Tiantan Hospital (1) · Charite University, Berlin, Germany (1) · Columbia University (1) · Diakonhjemmet Hospital (1) · Fundación Santa Fe de Bogota (1) · German University in Cairo (1) · Janssen Research & Development, LLC (1) · King Edward Medical University (1)
China (8) · United States (5) · Argentina (4) · Brazil (4) · Germany (4) · Italy (4) · Russia (4) · South Korea (4) · Spain (4) · Australia (3) · Canada (3) · France (3) · Mexico (3) · Peru (3) · Puerto Rico (3)
Gregg Silverman, MD (1) · Gulraiz Iqbal, MBBS (1) · Haijie Ji, MD (1) · Hsiao-Yi Lin, PHD (1) · Joan M Bathon, MD (1) · Liming Wang, MD (1) · Marte S Heiberg, MD, PhD (1) · Min Yang, doctor (1)
PMID 29244149, PMID 30649524, PMID 32508063, PMID 20952478, PMID 24941177, PMID 25047021, PMID 26056119, PMID 27175296, PMID 27493790, PMID 27909081, PMID 28143815, PMID 28866645, PMID 29696833, PMID 29761420, PMID 30177460, PMID 30407745, PMID 30446575, PMID 31087542, PMID 31431998, PMID 31481566, PMID 31880308, PMID 32816215, PMID 33057725, PMID 33059710, PMID 33127856, PMID 34057820, PMID 34870800, PMID 35577477, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36814062, PMID 36931693, PMID 37405710, PMID 37453736, PMID 37773189, PMID 38233075, PMID 38357391, PMID 38453475, PMID 38883150, PMID 38958913, PMID 39192350, PMID 39250723
2009 (2), 2005 (1), R01AR050026 (1)